Novo Holdings Engages in Strategic Investment for Biotech Innovation
Novo Holdings has taken a significant step in the biotech sector by participating in a €90 million Series A financing round for Orbis Medicines. This investment is aimed at supporting the development of Orbis' pipeline, which focuses on next-generation oral macrocycle drugs.
Orbis Medicines and Its Cutting-Edge Technology
Orbis' innovative nGen platform utilizes advanced automated chemistry and machine learning to explore the design of oral macrocycles. This approach positions Orbis uniquely to develop novel therapies that can transform patient care.
Leadership Transition at Orbis
Morten Graugaard, a partner at Novo Holdings, has recently been appointed as the Chief Executive Officer of Orbis Medicines. Graugaard's leadership will guide the company through its ambitious plans in the evolving pharmaceutical landscape.
The Genesis of Orbis Medicines
Founded in 2021, Orbis Medicines emerged from the Seed Investments team at Novo Holdings. The company is dedicated to pioneering oral macrocycle drug discovery, building on groundbreaking work from experts like Professor Christian Heinis and Sevan Habeshian at the Swiss Federal Institute of Technology in Lausanne.
Focus on Macrocycle Development
Macrocycles represent a diverse group of compounds known for their therapeutic properties. However, creating effective oral formulations has been a challenge. Orbis aims to overcome this by developing oral alternatives for blockbuster biologics that maximize patient benefits.
Advantages of Oral Drug Administration
The transition to oral drugs presents several advantages, including improved dose control and ease of intake. This shift is crucial for reaching broader patient populations who might benefit from these therapies.
Words from Company Leaders
João Ribas, Principal at Novo Holdings, expressed excitement about Orbis's future, noting, "The combination of automated chemical synthesis and machine learning fueled our desire to support Orbis right from its inception. Morten's appointment marks a new chapter for the team, and we look forward to seeing their progress in the macrocycle arena."
Orbis Medicines' Therapeutic Pipeline
The pipeline developed by Orbis is set to target indications that have been validated by intravenous biologics. Their patented nCycle candidates are designed specifically for enhanced oral bioavailability, which is critical for therapeutic success.
About Novo Holdings
Novo Holdings A/S serves as a pivotal entity in managing the assets of the Novo Nordisk Foundation. The organization's mission is to enhance global health and societal sustainability while delivering attractive long-term returns. They invest in life sciences companies at various stages through their specialized teams, reinforcing their role as a leader in the biotech investment landscape.
A Look Ahead at Investments and Impacts
With total assets surpassing EUR 149 billion, Novo Holdings remains committed to strategic investments in groundbreaking life sciences companies. Their focus on companies like Orbis Medicines showcases the aim to foster innovation that could potentially transform healthcare for many.
Frequently Asked Questions
What is the main focus of the investment by Novo Holdings?
The investment is aimed at supporting the development of oral macrocycle drugs through Orbis Medicines' innovative technology platform.
Who has been appointed as the CEO of Orbis Medicines?
Morten Graugaard has taken on the role of CEO after holding an executive position on the board.
What technology does Orbis Medicines use?
Orbis employs a unique nGen platform that combines automated chemistry and machine learning for drug development.
What are macrocycles and their significance?
Macrocycles are diverse compounds known for their therapeutic properties, which Orbis aims to harness for oral drug formulations, overcoming historical challenges.
What is the mission of Novo Holdings?
Novo Holdings aims to improve health and sustainability while generating attractive long-term returns from its investments.
